Introduction & Objective: This study investigated clinical parameters in a real-world population of Chinese individuals with T2D treated with IDegAsp in routine clinical practice.

Methods: This 20-week, prospective, single-arm, open-label, non-interventional study (NCT05221580) included adults with T2D receiving anti-hyperglycemic treatment (oral antidiabetic drugs [OADs] only, basal insulin [±OAD], basal-bolus insulin [±OAD], premixed insulin [±OAD] or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ± insulin [±OAD]), initiating or switching to IDegAsp. Primary endpoint: change in HbA1c from baseline (BL) to end of study (EOS). Secondary endpoints: change in fasting plasma glucose (FPG) and hypoglycemic episode incidence.

Results: Of 878 adults (57.4% male; mean age 59.6 yrs), patients generally received IDegAsp once (47.2%) or twice (52.2%) daily. Initiating/switching to IDegAsp significantly lowered mean [95% CI] HbA1c (-1.27% [-1.36;-1.19], p<0.0001), with similar decreases in all prior treatment groups (Figure). Mean [95% CI] FPG fell significantly (-1.61 mmol/L [-1.81;-1.41], p<0.0001). Non-severe hypoglycemic episodes in last 20 wks were reduced at EOS vs BL (45 vs 115 patients).

Conclusion: Initiating/switching to IDegAsp improved glycemic control in a real-world population of Chinese adults with T2D.

graphic
View largeDownload slide
Disclosure

L. Guo: Consultant; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Eli Lilly and Company, Hengrui (USA) Ltd., Dreisamtech, Dongbao, Gan & Lee, Hansoh. L. Chen: None. F. Zhao: None. X.Y. Liu: None. H. Ding: None. K. Wang: None. Z. Xing: None. V. Shankarappa: Employee; Novo Nordisk A/S. G. Chaudhary: None.

Funding

Novo Nordisk

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.